Brief: Prescient Therapeutics Says U.S. FDA Grants PTX-100 Additional Orphan Drug Designation
09/03/2023 01:20
March 9 (Reuters) - Prescient Therapeutics Ltd PTX.AX :
* U.S. FDA GRANTS PTX-100 ADDITIONAL ORPHAN DRUG DESIGNATION
(ODD)
FOR ALL T CELL LYMPHOMAS
Source text for Eikon: ID:nASXp1RJ3
Further company coverage: PTX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Prescient Therapeutics
See all newsAustralia's Prescient Therapeutics falls on discounted share placement
Brief: Prescient Therapeutics Raises A$4.8 Million Via SPP, A$1.2 Million In Placement
Brief: Prescient Therapeutics Says Trading Halt Requested
Australia's Prescient Therapeutics hits near 2-month low on discounted raise
Brief: Prescient Therapeutics Secures EU Authorisation To Commence PTX-100 Clinical Trial